Center for Tumor Biotherapy, The First Affiliated Hospital & College of Public Health, Zhengzhou University, Zhengzhou, Henan 450052, China ; Department of Biological Sciences & Border Biomedical Research Center, The University of Texas at El Paso, El Paso, TX 79968, USA.
Center for Tumor Biotherapy, The First Affiliated Hospital & College of Public Health, Zhengzhou University, Zhengzhou, Henan 450052, China.
J Immunol Res. 2014;2014:326593. doi: 10.1155/2014/326593. Epub 2014 Apr 27.
Ovarian cancer is one of the leading causes of cancer-related deaths among women. There is an urgent need of better approaches for the identification of appropriate biomarkers in the early detection of ovarian cancer. The aim of this study was to elucidate the significance of autoantibodies against insulin-like growth factor II mRNA-binding proteins (IMPs) in patients with ovarian cancer. In this study, autoantibody responses to two members (IMP1 and p62/IMP2) of IMPs were evaluated by enzyme-linked immunosorbent assay (ELISA), western blotting, and indirect immunofluorescence assay in sera from patients with ovarian cancer and normal human individuals. The results have demonstrated that both IMP1 and p62/IMP2 can induce relatively higher frequency of autoantibody responses in patients with ovarian cancer (26.5% and 29.4%) compared to normal individuals (P<0.01). Our preliminary data suggest that IMP1 and p62/IMP2 can stimulate autoimmune responses in ovarian cancer, and anti-IMP1 and anti-p62/IMP2 autoantibodies could be used as potential biomarkers in immunodiagnosis of ovarian cancer.
卵巢癌是导致女性癌症相关死亡的主要原因之一。因此，迫切需要更好的方法来识别卵巢癌早期检测中的合适生物标志物。本研究旨在阐明针对胰岛素样生长因子 II mRNA 结合蛋白（IMP）的自身抗体在卵巢癌患者中的意义。在这项研究中，通过酶联免疫吸附测定（ELISA）、Western blot 和间接免疫荧光分析评估了卵巢癌患者和正常个体血清中两种 IMP（IMP1 和 p62/IMP2）成员的自身抗体反应。结果表明，与正常个体相比，IMP1 和 p62/IMP2 均可诱导卵巢癌患者产生相对较高频率的自身抗体反应（26.5%和 29.4%）（P<0.01）。我们的初步数据表明，IMP1 和 p62/IMP2 可在卵巢癌中刺激自身免疫反应，抗-IMP1 和抗-p62/IMP2 自身抗体可用作卵巢癌免疫诊断的潜在生物标志物。
